Clinical analyses of 80 hemophagocytic lymphohistiocytosis patients with Epstein-Barr viremia
Zeng, X.; Wei, N.; Wang, Y.; Wang, J.; Zhang, J.; Wu, L.; Li, S.; Tang, R.; Huang, W.; Chen, J.; Pei, R.; Wang, Z.
Zhonghua Yi Xue Za Zhi 94(36): 2841-2843
2014
ISSN/ISBN: 0376-2491 PMID: 25534103 Document Number: 677893
To analyze the clinical characteristics, treatment and prognosis of hemophagocytic lymphohistiocytosis (HLH) patients with Epstein-Barr viremia (EBV). A retrospective study was conducted to analyze the clinical data of 80 HLH patients aged ≥ 14 years with EBV-DNA >1 000 copies/ml in peripheral blood from 2008 to 2013. There were EBV-HLH (n = 46), HLH-associated lymphoma (n = 30) and primary HLH (n = 4). Among the relevant laboratory parameters, inter-group statistical differences existed only in alanine transaminase (ALT) and aspartate aminotransferase (AST) (P = 0.021, 0.035). The median follow-up period was 2.0 (0.5-20.0) months. And the 1-month, 3-month, 6-month and 12-month overall survival rates were 58.8%, 37.5%, 29.7% and 19.6% respectively. HLH patients with EBV have a pernicious clinical course with a poor prognosis. And it makes little sense for distinguishing HLH-associated lymphoma from EBV-HLH through routine laboratory tests.